Login / Signup

4-Substituted Thieno[3,2- d ]pyrimidines as Dual-Stage Antiplasmodial Derivatives.

Prisca LagardèreRomain MustièreNadia AmanzougagheneSébastien HutterJean-François FranetichNadine AzasPatrice VanellePierre VerhaegheNicolas PrimasDominique MazierNicolas MasurierVincent Lisowski
Published in: Pharmaceuticals (Basel, Switzerland) (2022)
Malaria remains one of the major health problems worldwide. The increasing resistance of Plasmodium to approved antimalarial drugs requires the development of novel antiplasmodial agents that can effectively prevent and/or treat this disease. Based on the structure of Gamhepathiopine, a 2- tert -butylaminothieno[3,2- d ]pyrimidin-4(3 H )-one hit, active on the sexual and asexual stages of the parasite and thanked for the introduction of various substituents at position 4 of the thienopyrimidine core by nucleophilic aromatic substitution and pallado-catalyzed coupling reactions, a series of 4-substituted thieno[3,2- d ]pyrimidines were identified as displaying in vitro activities against both the erythrocytic stage of P. falciparum and the hepatic stage of P. berghei. Among the 28 compounds evaluated, the chloro analogue of Gamhepathiopine showed good activity against the erythrocytic stage of P. falciparum, moderate toxicity on HepG2, and better activity against hepatic P. berghei parasites, compared to Gamhepathiopine.
Keyphrases
  • plasmodium falciparum
  • mental health
  • molecular docking
  • room temperature
  • oxidative stress
  • risk assessment
  • human health
  • drug induced
  • health promotion